Medjitna T D E, Stadler C, Bruckner L, Griot C, Ottiger H P
Institute of Virology and Immunoprophylaxis, Mittelhäusern, Switzerland.
Dev Biol (Basel). 2006;126:261-70; discussion 327.
For licensing purposes, besides the immunogenic aspects, deoxyribonucleic acid (DNA) vaccines present safety considerations that must be critically assessed during preclinical or/and clinical safety studies. The major concerns with regard to safety are integration of the plasmid DNA into the host genome, adverse immunopathological effects, the formation of anti-DNA antibodies resulting in auto-immune disease and the use of novel molecular adjuvants. Moreover, for veterinary vaccines intended to be used in husbandry animals, food safety aspects will become an important issue. All new vaccine candidates should therefore be thoroughly tested in target animals, keeping in mind that for food producing animals, the products will be consumed. Finally, a further safety aspect of interest concerns the possible spread of genetic material to the environment, by the potential transformation of the environmental microflora with only a few copies of complete or fragmented plasmid. These are issues that need to be considered in the final scientific decisions underpinning the registration of vaccines. Thus, to establish criteria for guidance and regulations for industry and licensing authorities, a project has been initiated to assess such risks of plasmid DNA vaccinations. Major emphasis will be placed on aspects such as the biodistribution of plasmid in vaccinated animals. This paper is intended as a contribution to the debate on the use of biotechnology in the future and should facilitate further discussions on the various safety aspects of DNA-based immunisations.
出于许可目的,除了免疫原性方面,脱氧核糖核酸(DNA)疫苗还存在安全方面的考量,在临床前或/和临床安全性研究中必须对这些考量进行严格评估。与安全性相关的主要问题包括质粒DNA整合到宿主基因组中、不良免疫病理效应、导致自身免疫性疾病的抗DNA抗体的形成以及新型分子佐剂的使用。此外,对于打算用于饲养动物的兽用疫苗,食品安全方面将成为一个重要问题。因此,所有新的候选疫苗都应在目标动物中进行全面测试,要记住对于食用动物而言,这些产品将会被食用。最后,另一个值得关注的安全方面涉及遗传物质可能向环境中的传播,这是由于环境微生物群有可能仅通过几份完整或片段化的质粒就被转化。这些都是在支撑疫苗注册的最终科学决策中需要考虑的问题。因此,为了为行业和许可当局制定指导标准和法规,已经启动了一个项目来评估质粒DNA疫苗接种的此类风险。主要重点将放在诸如质粒在接种动物体内的生物分布等方面。本文旨在为未来关于生物技术应用的辩论做出贡献,并应促进关于基于DNA免疫的各种安全方面的进一步讨论。